Journal List > Korean J Schizophr Res > v.17(1) > 1122196

Korean J Schizophr Res. 2014 Apr;17(1):5-11. Korean.
Published online Apr 24, 2014.
Copyright © 2014 Korean Society for Schizophrenia
Schizophrenia Spectrum Disorder in DSM-5 : Is this a New Change?
Chul-Hyun Cho, MD, PhD and Heon-Jeong Lee, MD, PhD
Department of Psychiatry, Korea University College of Medicine, Seoul, Korea.

Address for correspondence: Heon-Jeong Lee, Department of Psychiatry, Anam Hospital, Korea University College of Medicine, 73 Inchon-ro, Seongbuk-gu, Seoul 136-705, Korea. Tel: 02-920-6721, Fax: 02-929-7679, Email:
Received Mar 08, 2014; Revised Mar 24, 2014; Accepted Mar 25, 2014.


The American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth version (DSM-5) finally introduced in 2013. Psychiatrists and researchers of neuroscience were looking forward that DSM-5 will introduce a new paradigm of diagnostic criteria. However, they have criticized on DSM-5 about not including of neurobiological criteria after DSM-5 published. Since schizophrenia spectrum disorder is heterogeneous and hard to diagnose correctly, we can guess that there might be a big affliction in preparation of DSM-5. Diagnostic criteria of schizophrenia spectrum disorder in DSM-5 changed in several points including changes of Criteria A of schizophrenia. The most outstanding change is the elimination of subtypes of schizophrenia, and introducing of Clinician-Rated Dimensions of Psychosis Symptom Severity for further division into homogenous subgroups depending on psychosis symptoms. Until now, the results of various neurobiological investigations are not consistent, so neurobiological criteria of schizophrenia spectrum disorder deserved no inclusion in DSM-5. Thinking comprehensively, DSM-5 might decide to choose stability rather than challenge. In the future, the diagnostic criteria of schizophrenia spectrum disorder in DSM will progress with inclusion of neurobiological criteria, and researches of schizophrenia spectrum disorder will make advance that match changes in progression of DSM.

Keywords: Schizophrenia spectrum disorder; DSM-5


1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders : DSM-5. 5th Edition. 2013.
2. Kraepelin E. In: Dementia praecox and paraphrenia. Livingstone; 1919.
3. Bleuler E. American Institute for Psychological Research. In: Dementia Praecox: Or the Group of Schizophrenias. American Institute for Psychological Research; 1991.
4. Schneider K. In: Clinical Psychopathology. New York; 1959.
5. Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res 2013;150:3–10.
6. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res 2009;110:1–23.
7. Kendell R, Jablensky A. Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiatry 2003;160:4–12.
8. Kapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry 2012;17:1174–1179.
9. Bromet EJ, Kotov R, Fochtmann LJ, Carlson GA, Tanenberg-Karant M, Ruggero C, et al. Diagnostic shifts during the decade following first admission for psychosis. Am J Psychiatry 2011;168:1186–1194.
10. Korver-Nieberg N, Quee PJ, Boos HB, Simons CJ. The validity of the DSM-IV diagnostic classification system of non-affective psychoses. Aust N Z J Psychiatry 2011;45:1061–1068.
11. Haahr U, Friis S, Larsen TK, Melle I, Johannessen JO, Opjordsmoen S, et al. First-episode psychosis: diagnostic stability over one and two years. Psychopathology 2008;41:322–329.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R. American Psychiatric Association; 1987.
13. Tanenberg-Karant M, Fennig S, Ram R, Krishna J, Jandorf L, Bromet EJ. Bizarre delusions and first-rank symptoms in a first-admission sample: a preliminary analysis of prevalence and correlates. Compr Psychiatry 1995;36:428–434.
14. Peralta V, Cuesta MJ. Diagnostic significance of Schneider's first-rank symptoms in schizophrenia. Comparative study between schizophrenic and non-schizophrenic psychotic disorders. Br J Psychiatry 1999;174:243–248.
15. Jansson LB, Parnas J. Competing definitions of schizophrenia: what can be learned from polydiagnostic studies? Schizophr Bull 2007;33:1178–1200.
16. Nordgaard J, Arnfred SM, Handest P, Parnas J. The diagnostic status of first-rank symptoms. Schizophr Bull 2008;34:137–154.
17. Ihara K, Morgan C, Fearon P, Dazzan P, Demjaha A, Lloyd T, et al. The prevalence, diagnostic significance and demographic characteristics of Schneiderian first-rank symptoms in an epidemiological sample of first-episode psychoses. Psychopathology 2009;42:81–91.
18. Allardyce J, McCreadie RG, Morrison G, van Os J. Do symptom dimensions or categorical diagnoses best discriminate between known risk factors for psychosis? Soc Psychiatry Psychiatr Epidemiol 2007;42:429–437.
19. Shinn AK, Heckers S, Ongur D. The special treatment of first rank auditory hallucinations and bizarre delusions in the diagnosis of schizophrenia. Schizophr Res 2013;146:17–21.
20. Tandon R, Bruijnzeel D, Rankupalli B. Does change in definition of psychotic symptoms in diagnosis of schizophrenia in DSM-5 affect caseness? Asian J Psychiatr 2013;6:330–332.
21. Black DW, Boffeli TJ. Simple schizophrenia: revisited. Compr Psychiatry 1990;31:344–349.
22. David AS, Appleby L. Diagnostic criteria in schizophrenia: accentuate the positive. Schizophr Bull 1992;18:551–557.
23. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 2006;32:238–245.
24. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32:214–219.
25. Messinger JW, Tremeau F, Antonius D, Mendelsohn E, Prudent V, Stanford AD, et al. Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin Psychol Rev 2011;31:161–168.
26. Liemburg E, Castelein S, Stewart R, van der Gaag M, Aleman A, Knegtering H. Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. J Psychiatr Res 2013;47:718–725.
27. Keefe RS. Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry 2008;7:22–28.
28. Tandon R, Maj M. Nosological status and definition of schizophrenia: Some considerations for DSM-V and ICD-11. Asian J Psychiatr 2008;1:22–27.
29. Depp CA, Moore DJ, Sitzer D, Palmer BW, Eyler LT, Roesch S, et al. Neurocognitive impairment in middle-aged and older adults with bipolar disorder: comparison to schizophrenia and normal comparison subjects. J Affect Disord 2007;101:201–209.
30. Reichenberg A, Harvey PD, Bowie CR, Mojtabai R, Rabinowitz J, Heaton RK, et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull 2009;35:1022–1029.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition: DSM-IV-TR®. American Psychiatric Association; 2000.
32. McGlashan TH, Fenton WS. Classical subtypes for schizophrenia: literature review for DSM-IV. Schizophr Bull 1991;17:609–632.
33. Linscott RJ, Allardyce J, van Os J. Seeking verisimilitude in a class: a systematic review of evidence that the criterial clinical symptoms of schizophrenia are taxonic. Schizophr Bull 2010;36:811–829.
34. Peralta V, Cuesta MJ. The relationship between syndromes of the psychotic illness and familial liability to schizophrenia and major mood disorders. Schizophr Res 2007;91:200–209.
35. Picardi A, Viroli C, Tarsitani L, Miglio R, de Girolamo G, Dell'Acqua G, et al. Heterogeneity and symptom structure of schizophrenia. Psychiatry Res 2012;198:386–394.
36. Maj M, Pirozzi R, Formicola AM, Bartoli L, Bucci P. Reliability and validity of the DSM-IV diagnostic category of schizoaffective disorder: preliminary data. J Affect Disord 2000;57:95–98.
37. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994;51:849–859.
discussion 863-844.
38. Malaspina D, Owen MJ, Heckers S, Tandon R, Bustillo J, Schultz S, et al. Schizoaffective Disorder in the DSM-5. Schizophr Res 2013;150:21–25.
39. Phillips KA, Wilhelm S, Koran LM, Didie ER, Fallon BA, Feusner J, et al. Body dysmorphic disorder: some key issues for DSM-V. Depress Anxiety 2010;27:573–591.
40. Heckers S, Tandon R, Bustillo J. Catatonia in the DSM--shall we move or not? Schizophr Bull 2010;36:205–207.
41. Barch DM, Bustillo J, Gaebel W, Gur R, Heckers S, Malaspina D, et al. Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5. Schizophr Res 2013;150:15–20.
42. Carpenter WT. Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophr Bull 2009;35:841–843.
43. Woods SW, Walsh BC, Saksa JR, McGlashan TH. The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res 2010;123:199–207.
44. Boonstra N, Klaassen R, Sytema S, Marshall M, De Haan L, Wunderink L, et al. Duration of untreated psychosis and negative symptoms--a systematic review and meta-analysis of individual patient data. Schizophr Res 2012;142:12–19.
45. Linscott RJ, van Os J. An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol Med 2013;43:1133–1149.
46. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012;69:220–229.
47. Fusar-Poli P, Bechdolf A, Taylor MJ, Bonoldi I, Carpenter WT, Yung AR, et al. At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull 2013;39:923–932.
48. Tsuang MT, Van Os J, Tandon R, Barch DM, Bustillo J, Gaebel W, et al. Attenuated psychosis syndrome in DSM-5. Schizophr Res 2013;150:31–35.
49. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Royal College of Psychiatrists; 1992.
50. Gaebel W. Status of psychotic disorders in ICD-11. Schizophr Bull 2012;38:895–898.
51. Cuthbert BN, Insel TR. Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria project. Schizophr Bull 2010;36:1061–1062.
52. Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry 2014;13:28–35.
Similar articles

Psychosocial Stressors and Ratings in Child and Adolescent Psychiatric Disorders

Schizoaffective Disorder

A Case-Controlled Study of Cognitive Behavioral Therapy for Patients with Schizophrenia Having Violence-Related Crime

Recent Advances in Diagnosis and Treatment of Insomnia Disorder

How Can We Differentiate Schizoaffective Disorder from Mood Disorder with Psychotic Feature?